Teratogenic Effects of Third-generation Antiepileptic Drug, Pregabalin: An In vivo Study

Author(s): Krishna Pal Singh*, Kiran Gupta.

Journal Name: Current Drug Safety

Volume 13 , Issue 2 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In the recent past, many third-generation antiepileptic drugs (AEDs) including Pregabalin (PGB) were launched for the treatment of diverse forms of epilepsy with better efficacy and safety profile than first-and-second-generation AEDs, but their teratogenic safety has not been established so far.

Objective: The present study has been undertaken to evaluate the reproductive and teratogenic potential (external and skeletal) of a novel and third generation AED, PGB in pregnant albino rats.

Methods: In this study, pregnant subjects were exposed to clinically relevant doses (41, 82 and 123 mg) of PGB from gestation days 6-20, and sacrificed on GD-21, and their fetuses were collected and examined to identify the birth defects and skeletal anomalies.

Results: This study revealed that prenatal exposure to PGB induced dose-dependent substantial fetal resorptions, litter size, fetal length and weight; and variety of minor external and internal malformations in fetuses predominant with limbs, tail, eyes, abdomen including hemorrhages, and poor skeletal ossification.

Conclusion: Thus, PGB was found to be teratogenic in rats at equivalent therapeutic doses, hence precaution should be taken before prescribing PGB to pregnant women with epilepsy.

Keywords: Antiepileptic drugs, pregabalin, pregnancy, teratogenicity, birth defects, rat.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2018
Page: [113 - 121]
Pages: 9
DOI: 10.2174/1574886313666180402145645
Price: $58

Article Metrics

PDF: 31
HTML: 5